Plumb Pharmaceuticals
Plumb Pharmaceuticals Inc. is dedicated to solving problems of medication compliance with extended-release formulations of FDA-approved drugs. The company develops innovative drug delivery technologies, notably the Advanced Quantload (AQL™) platform, which enables drug release rates measured in months, not days. Their solutions aim to improve treatment efficacy and patient compliance, especially in areas like opioid addiction and chronic pain management. The company was founded in 2016 by Drs. Tim Heath and Lisa Krugner-Higby, professors at the University of Wisconsin-Madison, and is based in Madison, WI.
Industries
Nr. of Employees
small (1-50)
Plumb Pharmaceuticals
Patents
Products
Extended‑release injectable formulation of an FDA‑approved opioid antagonist
An investigational, patent‑protected long‑acting injectable formulation based on a lipid nanoparticle platform designed to extend effective dosing intervals (reported target ~6 weeks) for medication‑assisted therapy.
Advanced Quantload (AQL™) Platform
Plumb Pharmaceuticals' Advanced Quantload (AQL™) technology provides drug release rates measured in months, enabling extended-release formulations such as a single injection for an entire course of antibiotics or continuous long-term relief from chronic pain and addiction.
Advanced Quantload Platform (AQL™) #2
A platform technology for super extended-release drug delivery enabling release rates measured in months, suitable for long-term relief from chronic pain and addiction, and providing an entire course of antibiotics with a single injection.
AQL-Naltrexone
An anti-opioid drug formulation providing the longest-acting injectable medication assisted therapy option on the market, with an effective duration of 2 months.
extended release drug platform combined with naltrexone
An extended release drug platform combined with naltrexone, used to treat addiction to alcohol and opioids, providing a much longer duration than current market options, lasting up to eight weeks.
Extended‑release injectable formulation of an FDA‑approved opioid antagonist
An investigational, patent‑protected long‑acting injectable formulation based on a lipid nanoparticle platform designed to extend effective dosing intervals (reported target ~6 weeks) for medication‑assisted therapy.
Advanced Quantload (AQL™) Platform
Plumb Pharmaceuticals' Advanced Quantload (AQL™) technology provides drug release rates measured in months, enabling extended-release formulations such as a single injection for an entire course of antibiotics or continuous long-term relief from chronic pain and addiction.
Advanced Quantload Platform (AQL™) #2
A platform technology for super extended-release drug delivery enabling release rates measured in months, suitable for long-term relief from chronic pain and addiction, and providing an entire course of antibiotics with a single injection.
AQL-Naltrexone
An anti-opioid drug formulation providing the longest-acting injectable medication assisted therapy option on the market, with an effective duration of 2 months.
extended release drug platform combined with naltrexone
An extended release drug platform combined with naltrexone, used to treat addiction to alcohol and opioids, providing a much longer duration than current market options, lasting up to eight weeks.
Services
Design and development of extended‑release lipid nanoparticle formulations, optimization of manufacturing processes, and transfer of methods to contract manufacturers.
Preparation and review of chemistry, manufacturing and controls (CMC) materials and other regulatory documentation to support filings.
In vivo testing in animal models to evaluate release kinetics and pharmacokinetics of extended‑release lipid nanoparticle formulations.
Design and development of extended‑release lipid nanoparticle formulations, optimization of manufacturing processes, and transfer of methods to contract manufacturers.
Preparation and review of chemistry, manufacturing and controls (CMC) materials and other regulatory documentation to support filings.
In vivo testing in animal models to evaluate release kinetics and pharmacokinetics of extended‑release lipid nanoparticle formulations.
Expertise Areas
- Extended‑release drug delivery
- Lipid nanoparticle and liposome formulation
- Indirect/remote drug loading techniques
- Formulation process development and scale‑up
Key Technologies
- Liposomes / lipid nanoparticles
- Indirect (remote) drug loading via encapsulated sacrificial agent
- Subcutaneous depot injectable formulations
- High payload encapsulation methods
News & Updates
Earlier this year, Plumb Pharmaceuticals secured investment from the Winnow Fund, a Madison-based venture capital fund, and launched a new website.
New BIO Analysis Reveals Declining Pain Drug Pipeline and Underinvestment in New Addiction Therapies
A report from BIO shows that current investment in pain and addiction treatments is falling short, with many drugs failing to make it out of clinical trials.
A podcast episode featuring the CEO discussing the company's technology and market strategy.
Earlier this year, Plumb Pharmaceuticals secured investment from the Winnow Fund, a Madison-based venture capital fund, and launched a new website.
New BIO Analysis Reveals Declining Pain Drug Pipeline and Underinvestment in New Addiction Therapies
A report from BIO shows that current investment in pain and addiction treatments is falling short, with many drugs failing to make it out of clinical trials.
A podcast episode featuring the CEO discussing the company's technology and market strategy.